Together, these data suggest that, similar to genetic knockdown, pharmacological inhibition of PBK strongly reduces two hallmarks of cancer in prostate cancer cells, namely, invasive ability, via down-regulation of β-catenin-mediated production of MMP-2 and -9, and proliferation. This evidence concerns the gene MMP2 and prostate cancer.